Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

You'll Be Stunned by How Many Cancer Immunotherapies Are Being Developed


You'll Be Stunned by How Many Cancer Immunotherapies Are Being Developed

For years, chemotherapy was the best treatment that the world of medicine had to offer in fighting cancer. That's no longer true. A powerful new class of cancer drugs called immunotherapies has become increasingly effective at treating cancer. These immunotherapies, also known as immuno-oncology (I-O) drugs, harness the body's own immune system to fight cancer. And they're becoming more popular in the research community than you might imagine.

The Cancer Research Institute (CRI) just published the most comprehensive assessment ever of the state of research and development for immunotherapies. This report identified a staggering 2,004 immunotherapies in development or on the market across the world.

For cancer patients, this means there are more experimental I-O drugs than ever before that hold hope for more effective treatment. But there's also a downside to having so many drugs being researched.

Continue reading


Source: Fool.com

Gilead Sciences Inc Aktie

67,16 €
0,43 %
Die Gilead Sciences Inc Aktie verzeichnet heute einen leichten Gewinn von 0,43 %.
Die Community neigt bei Gilead Sciences Inc zu Buy-Einschätzungen, mit einigen mehr als Sell-Einschätzungen.
Das Kursziel von 84 € für Gilead Sciences Inc weist auf eine Steigerung von über 20% gegenüber dem aktuellen Kurs von 67.16 € hin.
Like: 0
Teilen

Kommentare